secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001372514-25-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials
--------------------------------------------------------------------------------

- Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.
- Cash & short-term investments $24.1M; runway extended into late 2027 beyond key data readouts.
- Initiating Phase 2 KLARITY trial for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa); first patient enrollment expected Q2 2025.
- Received $1.8M in reimbursed Q4 2024 R&D expenses from Laboratoires Théa; total $5.6M since collaboration began.
- R&D expenses $2.5M (up from $1.7M) due to clinical trial activities; G&A $1.5M up from $1.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000045/0001372514-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000045/kprx-20250509.htm
  HTML page:      https://secwatch.observer/filing/0001372514-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer